Medication updates

Read the latest updates on epilepsy medication, including medication shortages.

Always try to get your prescription to your pharmacy in good time – up to seven days before you need it. This will enable the pharmacist to source other supplies if they are out of stock.

Arrange for repeat prescriptions to be sent electronically to a pharmacy of your choice.

If you are experiencing difficulties accessing your medication, always try contacting the customer service desk listed on the patient information leaflet that comes with your medication.

If you still require help, please contact our Helpline on 01494 601400. 

All tablet doses of Accord Levetiracetam are currently out of stock and no re supply date has been provided.

There is a supply issue with Esliacarbamazapine 200mg.

 Torrent have advised us that a re-supply is expected in December 2024. 

Accord Carbamazepine 100mg/5ml oral suspension

The Department of Health and Social Care has made us aware that Accord’s carbamazepine 100mg/5ml oral suspension is experiencing supply issues and is likely to be out of stock until mid-August 2024.

The Department will be issuing guidance to the NHS shortly for how to manage the shortages. In some cases, affected patients may temporarily be prescribed a different brand, tablets that can be dissolved or carbamazepine in tablet form if they are able to swallow.

Anyone impacted by the shortage is advised to speak to their doctor about their treatment plan.

Tegretol (carbamazepine) 100mg/5ml liquid

Novartis have updated us that they are still experiencing supply issues with Tegretol 100mg/5ml liquid, due to manufacturing constraints. While stock is now arriving in the UK, they anticipate that it will take further time for supply to return to normal levels.

A Novartis spokesperson said: "We understand the importance of access to this product and that delays such as these can cause great uncertainty for patients and their families. We regularly update the Department of Health and Social Care on the situation, and we have also been liaising closely with patient groups, government and healthcare professionals to minimise disruption where possible.

"We are working to resolve this matter as quickly as possible and ensure future supply stability. In the meantime, we encourage any patient affected to speak with their doctor or pharmacist regarding their treatment during this period.”

Novartis have said that Tegretol in all other strengths and formats is continuing to be supplied to wholesalers as normal.

Precautionary recall of Desitin Lamotrigine 10mg/ml oral suspension

The Medicines and Healthcare products Regulatory Agency (MHRA) has made us aware of a Class 2 Medicines Recall for Lamotrigine 10mg/ml oral suspension from Desitin Pharma UK Ltd. This is due to possible inconsistencies in the amount of medicine in each dose provided to patients.

The recall is precautionary and the MHRA has currently received no confirmed reports of harm.

If you or a family member currently takes this medication, you will be contacted by your healthcare professional to arrange alternative treatment. It is very important that patients on this medication do not stop taking it before hearing from their doctor, as this could worsen symptoms or seizure control.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Keppra 500mg tablets - Braille error on some batches

The Medicines and Healthcare products Regulatory Agency (MHRA) have let us know that an error related to Braille has been identified on some packs of Keppra 500mg film-coated tablets.

Some batches of these tablets have been repackaged with the Braille message incorrectly stating the strength as 1000mg. The affected batches are manufactured by Doncaster Pharma Ltd and the incorrect Braille is printed on 70 per cent of the cartons on the parallel imported packs that have been repackaged by BModesto B.V.

There is no issue with the quality of the product, so the affected batches are not being recalled.

Please see the list of affected products in the medicines notification.

Lamotrigine tablets - various strengths (Accord)

Accord UK have told us that their stock levels of Lamotrigine tablets in 100, 200 and 50mg strengths are currently low. They have released batches of additional stock and are expecting their next delivery in June. They are expecting these measures to help them to meet forecast demand.

They are making separate plans for additional batches of 25mg tablets, and should see stock levels returning to normal in July. They said that they fully understand patients' concerns and are doing everything they can to get additional stock as quickly as possible.

If you are experiencing supply issues, please consult your GP who will be able to discuss your treatment plan.

Tegretol® (carbamazepine) 100mg/5ml Liquid

We have been advised by Novartis that Tegretol® (carbamazepine) 100mg/5ml Liquid will be out of stock from the end of April. This is due to manufacturing constraints.  Full stocks are expected to return to normal within one month. 

All other presentations (100mg, 200mg and 400mg Standard Release Tablets and 200mg and 400mg Prolonged Release Tablets) are currently being supplied to wholesalers as normal.

A spokesperson for Novartis said: “We understand the importance of access to this product and that delays such as these can cause great uncertainty for patients and their families. The Department of Health are aware of the situation, and we have also been liaising closely with patient groups, government and healthcare professionals to minimise disruption where possible.
 
“We are working to resolve this matter as quickly as possible. In the meantime, we encourage any patient affected to speak with their doctor or pharmacist regarding their treatment during this period.”
 

Desitin Diazepam 10mg/2.5ml rectal tubes

We have heard from the Department of Health and Social Care (DHSC) that Desitin have reported a shortage of their Diazepam 10mg/2.5ml rectal tubes until early May 2024.

DHSC has informed the NHS of the shortages, and this may mean that patients are temporarily prescribed an alternative medication or a lower strength of diazepam to make up the dose required.

If your doctor does change your medication, they should only do this following a review and make sure that you are talked through how to administer the alternative product. Please speak to your doctor as early as possible if you have any questions or concerns.

Tegretol Prolonged Release 200mg and 400mg tablets

We have asked Novartis for an update as we have heard that some people are still having difficulties getting hold of Tegretol (carbamazepine) Prolonged Release 200mg and 400mg tablets. Novartis had previously said that both strengths should be available for patients from early February.

Novartis have confirmed that both strengths are back in stock and being supplied to wholesalers, but it may take a short time for the situation to normalise. They have advised anyone affected who has a valid prescription to ask their pharmacist to contact Novartis customer care. They will be able to obtain stock on behalf of patients.

CustomerCare, Novartis (Gen) novartis.customercare@novartis.com

Telephone: +44 8457419442

Oxcarbazepine (Viatris) 150mg and 300mg shortages

We have been informed by the Department of Health that there is currently a shortage of some Oxcarbazepine (Viatris) 150mg and 300mg tablets. Other versions of the medication are available but may not be able to support increased demand.

Oxcarbazepine is a category 2 anti-seizure medication which means that switching between manufacturers’ products should be based on clinical judgement and consultation with the patient or carer. This should take into consideration seizure frequency, treatment history and any negative perceptions about any alternative products.

Where people are switched to an alternative version of the medication, they should report any side effects or increased seizure activity to their GP.

Anyone who is prescribed oxcarbazepine should consult their GP for further advice.

Full details of the shortages are below:

Oxcarbazepine 150mg tablets (Viatris) are out of stock until late March 2024.
Oxcarbazepine 150mg tablets (Trileptal®) remain available, however, cannot support the full increase in demand.
Oxcarbazepine 300mg tablets (Viatris) are out of stock until mid-February 2024.
Oxcarbazepine 300mg tablets (Morningside) remain available and can support increased demand.
Oxcarbazepine (Trileptal®) 60mg/ml oral suspension remains available, however, cannot support the increase in demand.

Where people have insufficient supplies to last until the re-supply date, advice to clinicians is:

• for those on a 300mg dose, prescribe generic oxcarbazepine 300mg tablets (Morningside)
• for those on a 150mg dose, consider prescribing generic oxcarbazepine 300mg tablets (Morningside), halved to provide a 150mg dose, particularly in those who are on a twice daily dose where the other half is taken the same day, ensuring they are counselled on how to halve a tablet, and to use a tablet cutter
• only prescribe Trileptal® 150mg tablets if the option to halve a tablet is not appropriate, as there are insufficient supplies to support the full demand

Where licensed products are unavailable, prescribers can consider prescribing unlicensed products from outside the UK following guidance from the Department of Health.
 

Lamotrigine 25mg tablets (Accord)

Accord Healthcare have updated us that their 25mg Lamotrigine tablets will be out of stock for the long-term, and they do not have a date yet for receiving new supply. All other strengths of their Lamotrigine tablets are in stock. 

Anyone affected by these supply issues should speak to their GP or pharmacist, who will be able to advise on treatment plans going forward.

Tegretol Prolonged Release 200mg and 400mg tablets

Novartis have updated us that they have now received stock of Tegretol (carbamazepine) 200mg prolonged release tablets and have shipped outstanding wholesaler orders.

They are still experiencing delays to supply of Tegretol 400mg prolonged release tablets, due to manufacturing issues, and are currently expecting new stock by the beginning of February.

Novartis are working with their manufacturing plant to increase capacity and resolve supply issues as quickly as possible. Any patients affected by delays are advised to speak to their pharmacist or doctor about their treatment plan during this period.

Tegretol Prolonged Release 200mg and 400mg tablets

Novartis have informed us that they are currently experiencing a delay to supply of Tegretol (carbamazepine) Prolonged Release 200mg and 400mg tablets, due to a manufacturing issue. Based on current information, they estimate that the 200mg prolonged release tablets will be available again for patients by week beginning 15 January, and the 400mg prolonged release tablets will be back in stock by the end of January.

They are working with their manufacturing plant to resolve the issue as quickly as possible, and recommend that any patient affected by the delays should speak to their doctor or pharmacist about their treatment plan.

Supplies of Tegretol 100mg liquid and the Standard Release tablets (100mg, 200mg, 400mg) are not affected and remain normal.

Piracetam (Nootropil) oral solution and tablets - various strengths

UCB Pharma have informed us that their Piracetam (Nootropil) oral solution has been discontinued, so stock levels are very depleted. If you are affected by this, please contact your GP who will be able to discuss your treatment plan.

They have also advised that the production date of Nootropil tablets (800mg and 1200mg) was moved to 20 November, which has led to some temporary local shortages. Stock levels should now start to recover in local wholesaler branches. If you experience local shortages of tablets, UCB advise that you should ask your pharmacy to contact Alliance Healthcare, as they will be able to send new stock to local branches where required.

Epistatus (Midazolam) 2.5mg/0.25mL oromucosal solution pre-filled oral syringes

Veriton Pharma has informed us that their Epistatus (Midazolam) 2.5mg/0/25mL oromucosal solution pre-filled oral syringes are out of stock until early 2024 due to a manufacturer issue. There are no supply issues with other strengths of Epistatus.

If you are experiencing supply issues, please consult your GP who will be able to discuss your treatment plan.

Lamotrigine Accord tablets - supply issues with some strengths

Accord Healthcare have updated us on the supply of some strengths of their Lamotrigine tablets:

• 25mg tablets - currently only available via Mawdsleys wholesalers.
• 50mg tablets - stock will be available very shortly.
• 100mg tablets - no current supply issues.
• 200mg tablets - stock available from the start of November.

If you are experiencing supply issues, please consult your GP who will be able to discuss your treatment plan.

Tegretol (carbamazepine) - 100mg supply issue

We have been informed by the global healthcare company, Novartis, that there is currently a supply issue with Tegretol (carbamazepine) 100mg tablets. All other Tegretol lines are available.

Carbamazepine is a category 1 anti-seizure medication according to MHRA guidance for prescribing drugs. This means that people should not be switched between versions of this medication but should be kept on the same type. 

If you are experiencing supply issues, please consult your GP who will be able to discuss your treatment plan. 

Oxcarbazepine (Trileptal®) - supply shortage

UPDATE 2 August 2023

Novartis says they are now able to supply both Oxcarbazepine (Trileptal®) 300mg and 600mg tablets. If anyone is experiencing supply issues, they should ask their pharmacist to call Novartis Customer Care team on 0845 741 9442. This information relates to England, Scotland and Wales. Anyone in Northern Ireland who is experiencing should call the customer care team for further details.

UPDATE 31 July 2023

Novartis has informed us that there are still supply issues with Oxcarbazepine (Trileptal®) 300mg tablets. However, all other variations are now available. If you are experiencing problems, please contact  Customer Care Co-ordinator at Novartis Pharmaceuticals UK Limited by emailing Tyrone.dean-morris@novartis.com, 01276 692255 www.novartis.com

Original post 23 June 2023

The Department of Health has warned that there will be supply issues with some dosages of oxcarbazepine (Trileptal®) until mid-July. The following dosages will be affected:

• Oxcarbazepine (Trileptal®) 300mg tablets will be out of stock from late June to mid-July 2023
• Oxcarbazepine (Trileptal®) 600mg tablets are out of stock now and will remain so until mid-July 2023.

Generic versions of both 300mg and 600mg oxcarbazepine tablets are available and are expected to meet increased demand.

Oxcarbazepine (Trileptal®) 150mg tablets and generic oxcarbazepine 150g tablets are also available but will not be able to support the increase in demand. Oxcarbazepine (Trileptal®) 60mg/ml oral suspension also remains available but will not be able to meet an increase in demand.

Advice to people taking Trileptal®

If you are taking Trileptal®, please seek the advice of your doctor or epilepsy specialist. If you have to switch to a different version of your medication, discuss any potential side effects with your doctor and make sure you inform them of any change in seizure control.

Advice for doctors

Doctors are being advised to identify people with epilepsy who are taking Trileptal®, and to prioritise them for any remaining stock. If the tablets are not available and the person has to be switched to a  generic version of the medication, they should be carefully monitored for adverse effects and a change in seizure control. People should be reassured that they are still taking the same drug at the same dosage but should report any side effects.

If switching to a generic version of the medication is not considered appropriate, advice should be sort from a specialist.

No new patients should be started on Trileptal until the shortage has been resolved.

RECALL Sabril 500 mg film-coated tablets & Sabril 500 mg granules for oral solution

The MHRA has issued a recall affecting some patients using Sabril tablets and Sabril granules (vigabatrin). This has been issued as a precautionary measure due to the detection of traces of tiapride in the batches of the source material of manufacturer for vigabatrin.

Sabril (vigabatrin) is indicated for adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics (under expert supervision) and monotherapy in the treatment of infantile spasms (West's syndrome). 
 
All patients should be advised not to discontinue Sabril tablets or Sabril granules without consulting with their prescriber. The risks of suddenly stopping medication for seizures/epilepsy is higher than the potential risk presented by the presence of tiapride. Sanofi UK have confirmed that no other batches are impacted, and other stock remains available

Vigabatrin (Sabril) 500mg tablets supply shortage

Sanofi has told us it is experiencing a shortage of vigabatrin (Sabril) 500 mg film-coated tablets in the UK and anticipate that this medicine will go out of stock at the end of June.

The shortage is due to a delay in the global supply of the active pharmaceutical ingredient used to manufacture vigabatrin. The company is working to resolve the issue and hopes that the medication will be back in stock by mid-July 2023.

In a statement, Sanofi said: “We sincerely apologise for any inconvenience and difficulty for patients and healthcare professionals that this supply shortage may cause. We are in constant communication with the UK Department of Health and Social Care (DHSC) to try to minimise the disruption for patients.”

Advice to people with epilepsy

If anyone taking the medication has concerns, they should contact their healthcare professional regarding treatment. Clinicians can contact Sanofi’s Medical Information Service for further information via email on uk-medicalinformation@sanofi.com or by telephone on +44 (0) 800 035 2525.

Any pharmacists who have enquiries relating to stock can contact Sanofi Customer Services on +44 (0)800 854 430. 

Adverse events should be reported. Reporting forms and information can be found at MHRA Yellow Card or search 'yellow card' in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to uk-drugsafety@sanofi.com
 

Supply of Frisium (clobazam) now restored

We have been informed by Sanofi that there is now a full supply of Frisium (clobazam) available in the UK.

There had been a delay in the renewal of the pharmaceutical company’s Controlled Drugs Licence but this has now been resolved and the medication is once again available to pharmacies.

Sanofi issued the following statement: 
“Sanofi currently has full supply of Frisium (clobazam) available in the UK (GB/NI).

Following an expedited review and renewal of our Controlled Drugs Licence by the UK Home Office, we are now able to make this medicine available to pharmacies. 

We regret any impact that the delay may have had on patients and healthcare professionals.

Should patients have issues obtaining supply from their pharmacist, the pharmacist can contact Sanofi Customer Services (+44 (0)800 854 430) for support.  

Should patients have any concerns about their treatment, they should speak to their clinician about treatment options.”

Oxcarbazepine Tabs Mylan 150Mg supply issue

There is currently a supply issue with Oxcarbazepine Tabs Mylan 150Mg X 50. Re-supply is expected in mid-June.

Mylan have informed us that both Oxcarbazepine Tabs 300Mg X 50 and 600Mg X 50 are available.

If pharmacies are experiencing problems with supply from their wholesaler, they should contact Mylan’s medical information department on 01707 853 000 and select option 1.

If you have concerns about your medication, always consult your doctor before your supply runs out. For emotional support, please call our Helpline on 01494 601400.
 

Shortage of Accord-Healthcare levetiracetam 250mg and 1000mg

We have been informed by Accord-Healthcare  that they are currently out of stock of 250mg and 1000mg levetiracetam. They do, however, have the 500mg and 750mg doses.

There are other versions of levetiracetam available. If you have any issues with your prescription, please contact your GP.

For more information  contact Accord-Healthcare's Medical Information team on 01271 385257 or visit www.accord-healthcare.co.uk
 

Frisium (clobazam) and Zimovane (zopiclone) supply issue

We have been informed by the pharmaceutical company, Sanofi, that they are currently unable to supply Frisium (clobazam) or Zimovane (zopiclone) in the UK.

Both theses medications require a Controlled Drugs Licence which is granted by the Home Office. There has been a delay in the renewal of Sanofi’s Controlled Drugs Licence for these two medicines. This is currently being reviewed by the UK Home Office.

This means that neither medication is available and anyone who is prescribed the drugs should consult their doctor about changing to another form of clobazam. 

Switching between versions of medication

Clobazam is classed as a category two drug under guidance from the medicines regulator, the MHRA. Anyone prescribed drugs in this category should only change to another version of the same drug after consultation with their doctor.

The following generic versions of clobazam are also available: Perizam, Tapclob and Zacco.

Statement from Sanofi

Sanofi are working to resolve the situation and are hoping that the Home Office will accelerate the renewal review process. The pharmaceutical company have issued the following statement: 

“We are currently unable to supply Frisium (clobazam) or Zimovane (zopiclone) in the UK (GB/NI).

These medicines require a Controlled Drugs Licence which is granted by the UK Home Office. There has been a delay in the renewal of Sanofi’s Controlled Drugs Licence for these two medicines. The UK Home Office is currently reviewing the licence renewal.

We regret the situation and any impact the delay may have on patients and healthcare professionals.

We are doing everything we can to seek an expedited licence renewal review process, and are in constant communication with the UK Home Office and the Department of Health and Social Care (DHSC) to find a solution that enables patient access to these medicines as soon as possible. We are also keeping the Medicines and Healthcare products Regulatory Agency (MHRA) informed of the renewal progress.

At this stage, we cannot confirm when the licence review process will be completed by the UK Home Office and Sanofi will be able to return to normal supply of these medicines. However as soon as we have an update this will be communicated with the healthcare community.

Where Frisium (clobazam) and/or Zimovane (zopiclone) are not available, patients are advised to refer to their treating doctor who may suggest an appropriate alternative treatment. The choice of alternative treatment should be made by the patient and healthcare professional together, considering the patient’s condition and the suitability of available alternatives. Patients and healthcare professionals can contact Sanofi Medical Information on uk-medicalinformation@sanofi.com or +44 (0) 800 035 2525.

Adverse events/Side effects should be reported. Reporting forms and information can be found atwww.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on 0800 0902 314. Alternatively, send via email to UK-drugsafety@sanofi.com.”
 

Sabril (vigabatrin) back in stock

Following recent supply issues, we have received the following statement from Sanofi assuring us that Sabril (vigabatrin) 500 mg film-coated tablets are now back in stock in the UK. There is currently a good level of supply for all formulations of Sabril in the UK and global issues are being resolved to protect long-term supplies.

“Following recent supply issues, Sanofi can confirm that Sabril (vigabatrin) 500 mg film-coated tablets are now back in stock in the UK. 

The recent shortage of Sabril (vigabatrin) medicines was initially the result of a delay in the global supply of the active pharmaceutical ingredient (API) used to manufacture vigabatrin from our current supplier. Sanofi has since contracted a second supplier of API to try to alleviate this issue and address delays in global production.  Continuing issues relating to API have affected a planned resupply to the UK in early 2023, and Sanofi is working globally on a long-term solution to these issues.

We sincerely apologise for the inconvenience and difficulty for patients and healthcare professionals that this supply shortage has caused. Sanofi has done everything it can to supply as soon as possible and is in constant communication with the UK Department of Health and Social Care (DHSC) to try to minimise any disruption for patients. 

Should patients have any issues obtaining supply from their pharmacist, the pharmacist can contact Sanofi Customer Services (+44 (0)800 854 430)) for support.

If patients have concerns about treatment, they should contact their healthcare professional regarding treatment. Clinicians can contact Sanofi’s Medical Information Service for further information via email on uk-medicalinformation@sanofi.com or by telephone on +44 (0)800 035 25 25.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Sanofi drug safety department on Tel: 0800 0902 314. Alternatively, send via email to UK@drugsafety@sanofi.com.”
 

Lamotrigine (Lamictal) shortage

We have been informed by GSK that lamotrigine (Lamictal 2mg and 5mg Dispersible) is temporarily out of stock in the UK. GSK have told us that they expect them to be back in stock, with an estimated delivery in late February 2023.

If you have any concerns about getting your usual medicine, please speak to your pharmacist or GP for advice.

You can get in touch with GSK Customer Support team via email for further information. For UK Pharma Customer Support: customercontactuk@gsk.com and UK Consumer Healthcare enquiries: customer.relationships@gsk.com

Switching between different brands of medication

It is important to have a consistent supply of your epilepsy medication. If the supply issue means you have to switch to a different version of lamotrigine, make sure this is with supervision from your doctor.

The updated advice by MHRA on switching between different manufacturers’ products can be read here : Antiepileptic drugs: updated advice on switching between different manufacturers’ products - GOV.UK (www.gov.uk)

Topiramate (Topamax) shortage

We have been advised by Janssen that there is currently a shortage of topiramate (Topamax) in the UK. Supply of this medication is usually made available through wholesalers, Alliance & Phoenix Healthcare.

Pharmacies experiencing issues in obtaining supply of topiramate should contact Janssen Customer Services on 01494 567 400 or by emailing JanssenUKCustomerServices@its.jnj.com

They can arrange for an emergency order form to be sent to the pharmacy for them to complete and return with a copy of the redacted prescription.

Janssen will then arrange a direct delivery to the pharmacy within 1-2 working days at no additional cost.

Safety review

In July 2022, the MHRA launched a safety review into topiramate. Read further details here.
It is important to never stop taking your medication without the supervision of a healthcare professional.
 

Epanutin (phenytoin) 30mg/5ml oral suspension supply issue

We have been informed by the Department of Health that there is a short-term supply issue with Epanutin (phenytoin) 30mg/5ml 500ml oral suspension.

The Department’s Medicines Supply Team has been working closely with Viatris, suppliers of Epanutin, to minimise any disruption for patients.

The next delivery in the UK is expected by the middle of next week. To ensure that existing supplies last until then, Viatris have implemented a system of prescription validation in primary care from today.

This means, that before dispensing a prescription for Epanutin oral suspension, the pharmacist must first validate the prescription with the wholesaler, Alliance. Once validated, Alliance will then release the medication direct to the pharmacy by the next day.

The patient may need to return to the pharmacy the following day to pick up their prescription.

Viatris took over supply of Epanutin (phenytoin) 30mg/5ml 500ml oral suspension from Pfizer in late 2021.
 

Epilim Chrono modified release - some local issues

We are aware that some people have experienced difficulties in accessing the following epilepsy medication:

•    Epilim Chrono modified release 200mg

The pharmaceutical company Sanofi has assured us that they have stock nationally, but there have been regional supply issues in some areas.
Anyone experiencing a problem should ask their pharmacist to contact Sanofi Customer Service line on 0800854430 who will be able to help.

Vimpat and Vimpat Liquid - no shortage but delivery issues

We are aware that some people have experienced difficulties in accessing the following epilepsy medication:

•    Vimpat 50mg
•    Vimpat liquid

The pharmaceutical company UCB has assured us that there are no supply issues, though there have been delivery issues in some areas resulting in local shortages.

If you experience a problem getting your prescription of Vimpat, please contact UCB Cares on
0800 2793177, email UCBCares.UK@ucb.com or visit https://www.ucbcares.co.uk